The FDA has approved Enspryng (satralizumab-mwge; Genentech) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
The FDA has accepted for Priority Review the Biologics License Application for aducanumab for the treatment of Alzheimer disease.
The FDA has granted Priority Review of the supplemental New Drug Application for ticagrelor, for use in combination with aspirin, to reduce the rate of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.
The FDA has approved Fintepla® (fenfluramine; Zogenix) oral solution for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.
Higher doses of deutetrabenazine appear to be safe and well tolerated in patients with Huntington disease who may require them to adequately control chorea.
Treatment with deutetrabenazine was found to be beneficial for both younger (<55 years) and older (≥55 years) patients with tardive dyskinesia, according to findings from a recently published post hoc analysis.
Zeposia is available for the treatment of relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Lemborexant is now available for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.
The FDA has approved solifenacin succinate LS oral suspension for the treatment of neurogenic detrusor overactivity in pediatric patients 2 years of age and older.
This sublingual film formulation of apomorphine was designed for use as a fast-acting, on-demand treatment for all types of motor off episodes.
